Parkinson’s dyskinesia drug

A new drug, which combats a side effect of a common Parkinson’s disease treatment, is entering clinical trials after successful studies in marmoset monkeys.

The drug, NXL-122, produced by pharma company Neurolixis, reduced the uncontrolled movement in marmosets with symptoms of Parkinson’s who were receiving a levodopa-based medicine, without affecting the efficiency of the treatment.

Levodopa-based medicines treat the muscle stiffness and tremors caused by Parkinson’s, but often result in the development of dyskinesia - involuntary movement which can affect a person’s ability to perform simple tasks, and affects up to 80% of patients after 10 years.

The new clinical trial will be funded by Parkinson’s UK and The Michael J. Fox Foundation, US, and co-ordinated by the Karolinska Institute in Sweden.

Copyright © 2019 European Animal Research Association, All rights reserved.

European Animal Research Association 

London Office

Abbey House, 74-76 St John Street
London EC1M 4DZ
Tel: +44 (0)20 3675 1245

Brussels Office
52 Rue Marie de Bourgogne, 1st Floor
1000 Brussels,


  • Twitter
  • Facebook
  • LinkedIn Social Icon
  • Facebook Social Icon
  • Twitter Social Icon
  • LinkedIn Social Icon